Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TKM-Ebola-Guinea
- Development stage
- Discontinued
- Lead developer
- Arbutus Biopharma
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
TKM-Ebola-Guinea is a lipid nanoparticle formulation containing two small interfering RNAs (siRNAs) specifically designed to target the Ebola virus Makona (Guinea) strain that caused the 2014–2015 West African outbreak. It is a modified version of TKM-Ebola, adapted to match the genomic sequence of the outbreak strain precisely. The siRNAs interfere with the viral polymerase (L protein) and viral protein 35 (VP35), thereby inhibiting viral replication via RNA interference. Developed by Tekmira Pharmaceuticals (now Arbutus Biopharma), the drug aimed to silence essential viral genes and was evaluated in a Phase II clinical trial in Sierra Leone, but development was discontinued due to lack of efficacy in patients with advanced disease[1][2][3][4][7].
- Brand names
- TKM-Ebola-Guinea
- Other names
- TKM-Ebola GuineaTKM-100802 siEbola-3TKM100802 siEbola-3TKM 100802 siEbola-3
02
Targets
Ebola virus RNA-directed RNA polymerase L mRNA (EBOV L mRNA)VP35 (Ebola virus VP35)L protein (Zaire ebolavirus polymerase L protein)
Beyond the preview
Go deeper on TKM-Ebola-Guinea.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TKM-Ebola-Guinea.